(d) what was the price of bulk drug and MAPE taken in the break up submitted by the company under price decontrol as per the provision of DPCO, 1981; and

(e) what steps have been taken to rectify the anomaly?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) Glybenclamide has been price decontrolled on the specific recommendation of the Kelkar Committee made in its Supplementary Report which was accepted by the then Government.

(b) to (d) The price of Glybenclamide Tablets (5mg per Tablet) had been fixed at Rs. 8.88 (without excise duty) for 10x10's pack under DPCO, 1987. As per the information made available to the Government by the company in April, 1991, its price is Rs. 19.00 (without excise duty). The company has taken the price of bulk drug Glybenclamide at Rs. 4995 per kg. and MAPE at 175 per cent.

(e) The recommendations of the Standing Committee with regard to the inclusion/exclusion of bulk drugs from the purview of DPCO, 1987 are still under examination of the Government.

Increase in Prices of Certain Medicines

1323. SHRI ASHOK NATH VERMA: Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that manufacturers of Imidil Skin Cream 1 per cent 5 gm., Fluthane 250 ml., intravel Sodium 1 gm, Festal Dregees 10's pack Eltroxin pack of 100, Dilosyn Expestorant, Testiviron Depot 250 mg per ml. have increased their prices without any justification;

(b) what is the names of the manufacturer of each medicine and what is the bulk drug on which each medicine is based;

(c) what is the indication for which each medicine is being marketed and what is the composition of each;

(d) what was the price of each medicine and bulk drug on which each medicine is baged before DPCO, 1987 and what is the present price; and

(e) what is the Material cost and MAPE taken by each manufacturer for each products as submitted under provision of price control?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) All these formulations are out of price control. In case of unusual increase in the price of a non-scheduled formulation, Government intervenes to bring it to a reasonable level. This intervention, however can be enforced only when the pre-tax return on the sales turnover of the company exceeds the limits mentioned in the Fifth Schedule to DPCO, 1987.

(b) and (c) These details are available in MIMS India, which is a priced publication.

(d) and (e) To the extent available, information has been given in the Annexure. (See Appendix CLXI, Announre No. 34).

No Reduction in Prices of Formulations based on Analgin

1324. SHRI ASHOK NATH VERMA: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 652 given in the Rajya Sabha on the 5th September, 1991 and state:

(a) whether it is a fact that for over ten months the prices of formulations based on Analgin were not reduced;

(b) whether it is a fact that such an action has given undue benefit to the producers;

(c) whether it is a fact that provision of DPEA has been abolished in DPCO. 1987; and

(d) if so, under what provision of DPCO, 1987 the amount over-charged by the producers could be recovered and what steps have been taken by Government in this regard?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) and (b) While answering Rajya Sabha Unstarred Question No. 652 on 5-9-1991, it was, *inter alia,* stated that BICP had pointed out certain anomalies and sought clarification thereon from the Department. These were sorted out subsequently. In the meantime price of Analgin was revised upwards by the Government. The present price of Analgin is higher than the pre-reduced price.

(c) and (d) Under paragraph 14 of the DPCO, 1987, Government has power to recover dues which have accrued on account of actions under the DPCO, 1979 into the Drugs Price Equalisation Account (DPEA). Further, under paragraph 15 of DPCO, 1987, Government is empowered to recover the amount accrued due to charging of prices higher than those fixed or notified by the Government under DPCO, 1987.

Prices of Price Decontrolled Medicines

1325. SHRI ASHOK NATH VERMA: Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that prices of price decontrolled medicines have gone up from 100 per cent to 900 per cent after the announcement of Drugs Price Control Order, 1987;

(b) what was the price of Triperial Tablets pack of 60, Honvan Tablets pack of 20, Honvan Injection ml, Colospa Tablets strip of 10 Tablets, Shield 15 grms, Jetomisol-I One Tablet before the announcement of Drugs Price Control Order, 1987 and what is the price in the month of November, 1991;

(c) what is the name of each producer, indication for which each is used, composition of each and name of bulk drug on which each is based; and

(d) what is the price of bulk drug, meterial cost and MAPE taken in each break up submitted by the producer as required under Drugs Price Control Order?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) Number of decontrolled formulations runs into thousands. It would therefore, not be possible to comment if the increase has been of the order of 100 per cent to 900 per cent. However, it may be noted that the wholesale price index for drugs and medicines, both controlled and decontrolled, has gone up from 122 in 1986-87 to 150 in 1990-91. Whole sale price Index for all commodities has gone up from 133 to 183 during the same period (Base 1981-82=100). Moreover, in case of unusual increase in the prices of non-scheduled formulations, Government intervenes. However this can be enforced only when the pre-tax return on sales turnover of the unit exceeds the limits prescribed in the Fifth Schedule to DPCO, 1987.

(b) to (d) Efforts required to collect the information would not be commensurate with the results that are likely to be achieved.

Non-furnishing of data by M/s. Hoechst

1326. CHOWDHARY RAM SEWAK: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 648 given in the Rajya Sabha on the 5th September, 1991 and state:

(a) whether it is a fact that M/s. Hoechst did not make available the entire data in accordance with the High Court Judgement;

(b) if so, what steps have been taker to report back to High Court;